CANbridge is a biotechnology company focused on developing and commercializing rare disease therapeutics in China.
Location: China, Beijing
Employees: 11-50
Total raised: $176M
Founded date: 2012
Investors 5
Date | Name | Website |
- | General At... | generalatl... |
- | Huangpu Ri... | hprpe.com |
- | RA Capital... | racap.com |
- | Qiming Ven... | qimingvent... |
- | Qiming Ven... | qimingvc.c... |
Funding Rounds 4
Date | Series | Amount | Investors |
05.12.2020 | Series E | $43M | - |
18.02.2020 | Series D | $98M | General At... |
23.05.2017 | Series B | $25M | - |
02.12.2014 | Series A | $10M | - |
Mentions in press and media 18
Date | Title | Description | Source |
16.10.2023 | CANbridge Announces Full Enrollment Reached in the Core Part... | BEIJING and BURLINGTON, Mass., Oct. 16, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (1228.HK... | en.prnasia... |
09.10.2023 | CANbridge Announces Marketing Approval of CAN108 (/LIVMARLI®... | LIVMARLI is the First and Only Treatment Approved in Taiwan for Cholestatic Pruritus in ALGS LIVMARL... | en.prnasia... |
06.09.2023 | CANbridge to Participate in Two Investor Conferences in Sept... | BEIJING and BURLINGTON, Mass., Sept. 6, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (HKEX:12... | en.prnasia... |
31.08.2023 | CANbridge Announces Interim Financial Results and Corporate ... | BEIJING and CAMBRIDGE, Mass., Aug. 31, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals, Inc. ("C... | en.prnasia... |
25.02.2021 | CANbridge Pharmaceuticals and Puma Biotechnology Agree to Te... | BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 25, 2021-- CANbridge Pharmaceuticals, Inc., a ... | oaoa.com/n... |
05.12.2020 | CANbridge Pharmaceuticals Completes $43 Million Series E Fin... | - | qimingvc.c... |
01.12.2020 | CANbridge Pharmaceuticals Closes $43 Million Series E Financ... | BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals Inc., a company developin... | citybizlis... |
19.02.2020 | Canbridge nabs $98M to develop rare disease treatments | Chinese drugmaker Canbridge Pharmaceuticals has raised $98 million in a Series D led by General Atla... | pitchbook.... |
18.02.2020 | CANbridge Pharmaceuticals Completes US$98 Million Series D F... | - | generalatl... |
18.02.2020 | CANbridge Pharmaceuticals Closes US$98M Series D Financing | CANbridge Pharmaceuticals Inc., a Beijing, China-based biopharmaceutical company developing innovati... | finsmes.co... |
Show more